Answers are grounded in this paper and cite their sources.
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Belantamab mafodotin (belamaf) targets BCMA expressing plasma cells and as a monotherapy is approved for heavily pretreated patients (pts) with relapsed/refractory (RR) multiple myeloma. Clonal plasma cells in light chain (AL) amyloidosis express BCMA; thus, belamaf could be a treatment option for patients with RRAL amyloidosis. Aims: To present an interim analysis of the prospective EMN27 study assessing the efficacy and safety of belamaf monotherapy in pts with RRAL amyloidosis. Methods: The ongoing prospective, open-label, multinational, phase 2 EMN27 study (NCT04617925) aims to enroll 36 pts with RRAL amyloidosis. Pts at Mayo cardiac stage 3B are excluded. Belamaf monotherapy at 2.5 mg/kg (or 1.92 mg/kg for toxicity) is administered every 6 weeks for up to 8 cycles. Pre-planned study analyses included an interim safety analysis (after 6 pts received ≥1 treatment cycle) and an efficacy analysis (after 13 pts were enrolled). The outcomes of both analyses were favorable and study enrollment is on-going. This descriptive analysis included pts initiating treatment ≥3 months before 31/12/2022 (cutoff date). Results: Twenty-five pts are included in this analysis (median age: 66 years [46–80]; male: 15 [60%]). Heart was involved in 19 pts (76.0%), other commonly involved organs were the kidneys (16 pts, 64%), peripheral nerves (6 pts, 24%), and soft tissue (5 pts, 20%). At baseline, most pts (19, 76%) had New York Heart Association class II symptoms and median N-terminal pro-brain natriuretic peptide, high-sensitivity troponin T, and dFLC were 1,197 ng/L (90–7,270), 35 ng/L (3–116), and 117 mg/L (38–2,791), respectively. The median number of prior treatment lines was 3 (1–10). Eighteen (72%) and 23 (92%) pts had previously received daratumumab and bortezomib. At cutoff, 6 (24%) pts were continuing study treatment, and 19 (76%) pts had discontinued mostly due to disease progression/inadequate response (9 pts, 36%) or adverse events (AE; 7 pts, 28%; 5 pts due to ocular AEs). Median belamaf administration in cycles was 2 (1–8). Eighty-two belamaf doses were given (2.5 mg/kg: 63, 1.92 mg/kg: 19). Nine (36%) pts had 15 belamaf dose holds, with median delay of 21 days from planned belamaf administration. At a median follow up of 11 months (4–22), the overall hematologic response rate (partial response or better) was 60%, VGPR was 36% (15 pts, 9 pts respectively; Table). Median time to first hematologic response was 15 days (1–148) and to VGPR 43 days (15–106; Table). At 1 and 3 months, the respective best hematologic response rate were 44% (11 pts) and 56% (14 pts) for all pts, while for pts with prior daratumumab exposure this was 33% (6 pts) and 50% (9 pts). For all pts, 3-month organ response rate was 20% (5 pts; Table). All pts experienced ≥1 AE, with 24 (96%) pts experiencing ocular AEs, 8 (32%) pts hematologic toxicity, and 4 (16%) pts cardiac disorders; no new cardiac or renal toxicity signals were observed. Three (12%) pts had a fatal AE, all considered unrelated to belamaf. Twenty-one (84%) pts had visual acuity reduced (grade [Gr]1: 3 (12%); Gr2: 7 [28%]; Gr3: 10 [40%]; Gr4: 1 [4%]), 19 (76%) keratopathy (Gr1: 8 [32%]; Gr2: 7 [28%]; Gr3: 4 [16%]; Gr4: 0 [0%]), and 5 (20%) visual impairment (Gr1: 1 [4%]; Gr2: 2 [8%]; Gr3: 1 [4%]; Gr4: 1 [4%]). Summary/Conclusion: In heavily pretreated pts with RRAL amyloidosis, belamaf monotherapy induced rapid responses without unexpected toxicity. Prolonged administration cycles could not prevent ocular toxicity. Results suggest belamaf could be a treatment option for patients with RRAL amyloidosis, a difficult to treat population.
No takes yet. Share an insight, caveat, or question.
Kastritis et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: